Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 6/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11304261 | 0.90 | DYRK1A (0.49) | DYRK1ADYRK1BNPC1TP53ROCK2 | |
| SCHEMBL10323582 | 0.90 | DYRK1A (0.48) | DYRK1ADYRK1BCXCR3TP53LMNA | |
| SCHEMBL10324510 | 0.85 | DYRK1A (0.68) | DYRK1ADYRK1B | |
| SCHEMBL10323240 | 0.84 | DYRK1A (0.47) | DYRK1ADYRK1BTP53LMNA | |
| SCHEMBL10323719 | 0.81 | DYRK1A (0.49) | DYRK1ADYRK1BNPC1ROCK2LMNA | |
| SCHEMBL10324491 | 0.79 | DYRK1A (0.70) | DYRK1ADYRK1B | |
| SCHEMBL10324084 | 0.79 | DYRK1A (0.48) | DYRK1ADYRK1BTP53LMNA | |
| SCHEMBL11950589 | 0.77 | DYRK1A (0.61) | DYRK1ADYRK1BCXCR3 | |
| SCHEMBL10446533 | 0.77 | DYRK1A (0.71) | DYRK1ADYRK1B | |
| SCHEMBL10447004 | 0.76 | DYRK1A (0.70) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DYRK1A 654/4885DYRK1B 570/4885CXCR3 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.